Group One Trading’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31M Sell
470,600
-395,300
-46% -$25.1M 0.06% 320
2025
Q4
$55M Sell
865,900
-299,000
-26% -$18.6M 0.1% 187
2025
Q3
$64M Sell
1,164,900
-1,641,500
-58% -$67.6M 0.11% 166
2025
Q2
$92.7M Buy
2,806,400
+1,981,900
+240% +$68.9M 0.21% 67
2025
Q1
$33.1M Buy
824,500
+466,300
+130% +$21.4M 0.1% 170
2024
Q4
$16.8M Sell
358,200
-295,600
-45% -$15.4M 0.04% 448
2024
Q3
$34.5M Buy
653,800
+359,000
+122% +$20M 0.1% 153
2024
Q2
$16M Sell
294,800
-142,300
-33% -$8.59M 0.06% 267
2024
Q1
$30.6M Sell
437,100
-750,100
-63% -$58M 0.12% 117
2023
Q4
$99.1M Buy
1,187,200
+1,119,300
+1,648% +$40.5M 0.26% 44
2023
Q3
$2M Buy
67,900
+43,200
+175% +$1.44M 0.01% 1646
2023
Q2
$806K Sell
24,700
-18,800
-43% -$696K ﹤0.01% 2556
2023
Q1
$1.53M Sell
43,500
-6,400
-13% -$261K 0.01% 1763
2022
Q4
$2.29M Buy
49,900
+24,300
+95% +$1.05M 0.01% 1719
2022
Q3
$1.24M Sell
25,600
-12,700
-33% -$611K ﹤0.01% 2340
2022
Q2
$1.5M Buy
38,300
+21,700
+131% +$874K ﹤0.01% 2322
2022
Q1
$611K Sell
16,600
-15,000
-47% -$533K ﹤0.01% 3603
2021
Q4
$1.44M Buy
31,600
+1,700
+6% +$65.6K ﹤0.01% 2957
2021
Q3
$1.07M Buy
29,900
+29,100
+3,638% +$857K ﹤0.01% 3341
2021
Q2
$16K Sell
800
-30,600
-97% -$718K ﹤0.01% 7312
2021
Q1
$730K Sell
31,400
-43,400
-58% -$927K ﹤0.01% 3598
2020
Q4
$1.55M Sell
74,800
-26,600
-26% -$486K ﹤0.01% 2255
2020
Q3
$2.19M Buy
101,400
+52,200
+106% +$1.22M 0.01% 1524
2020
Q2
$1.16M Sell
49,200
-177,800
-78% -$3.33M 0.01% 1893
2020
Q1
$2.68M Buy
227,000
+148,500
+189% +$1.89M 0.02% 857
2019
Q4
$833K Buy
78,500
+63,600
+427% +$653K 0.01% 2039
2019
Q3
$170K Sell
14,900
-3,100
-17% -$38.9K ﹤0.01% 3200
2019
Q2
$203K Buy
18,000
+4,000
+29% +$38.6K ﹤0.01% 2840
2019
Q1
$113K Sell
14,000
-2,200
-14% -$16.2K ﹤0.01% 3089
2018
Q4
$102K Sell
16,200
-4,100
-20% -$30.1K ﹤0.01% 3140
2018
Q3
$200K Buy
20,300
+17,000
+515% +$136K ﹤0.01% 3006
2018
Q2
$27K Sell
3,300
-28,200
-90% -$235K ﹤0.01% 4247
2018
Q1
$227K Sell
31,500
-15,100
-32% -$129K ﹤0.01% 2691
2017
Q4
$380K Buy
46,600
+34,100
+273% +$387K ﹤0.01% 2476
2017
Q3
$181K Sell
12,500
-12,800
-51% -$175K ﹤0.01% 2831
2017
Q2
$306K Sell
25,300
-19,000
-43% -$264K ﹤0.01% 2331
2017
Q1
$569K Buy
44,300
+30,700
+226% +$359K 0.01% 1765
2016
Q4
$165K Sell
13,600
-158,000
-92% -$1.68M ﹤0.01% 2552
2016
Q3
$1.57M Buy
171,600
+132,800
+342% +$1.39M 0.02% 974
2016
Q2
$368K Sell
38,800
-13,900
-26% -$114K ﹤0.01% 1952
2016
Q1
$372K Buy
52,700
+25,500
+94% +$186K 0.01% 1903
2015
Q4
$285K Buy
27,200
+1,300
+5% +$12.8K ﹤0.01% 2236
2015
Q3
$173K Sell
25,900
-30,500
-54% -$208K ﹤0.01% 2612
2015
Q2
$379K Sell
56,400
-2,900
-5% -$19K 0.01% 2013
2015
Q1
$402K Buy
59,300
+7,400
+14% +$55.3K 0.01% 1792
2014
Q4
$416K Buy
51,900
+16,800
+48% +$72.1K 0.01% 1691
2014
Q3
$124K Sell
35,100
-58,800
-63% -$247K ﹤0.01% 2806
2014
Q2
$449K Buy
93,900
+57,100
+155% +$348K 0.01% 1727
2014
Q1
$350K Buy
36,800
+24,800
+207% +$224K 0.01% 1946
2013
Q4
$78K Buy
+12,000
New +$78.8K ﹤0.01% 3256

Other funds holding CYTK

Group One Trading's CYTK Position: Q1 2026 in Review

Group One Trading reduced its Cytokinetics (CYTK) stake by 11% in Q1 2026, selling an estimated $2.75M and leaving 363,997 shares worth $24M. The position accounts for 0.05% of the portfolio, ranked #405.

Group One Trading first reported a position in CYTK in Q4 2013 and has held it in 36 quarters since. The position peaked at $25.9M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Group One Trading held 363,997 shares of Cytokinetics worth $24M as of Q1 2026.
  • Group One Trading sold 43,256 Cytokinetics shares in Q1 2026, an estimated $2.75M.
  • Cytokinetics made up 0.05% of Group One Trading's portfolio in Q1 2026, its #405 holding.
  • Group One Trading first reported a position in Cytokinetics in Q4 2013 and has held it in 36 quarters since.
  • Group One Trading's Cytokinetics position peaked at $25.9M in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.